|Dr. N. Anthony Coles Jr.||Pres, CEO & Exec. Chairman||921.37k||N/A||1960|
|Dr. John J. Renger Ph.D.||Chief Scientific Officer||639.69k||N/A||1969|
|Dr. Ramiro Sanchez||Chief Medical Officer||1.2M||N/A||1961|
|Ms. Kathy Y. Yi||Chief Financial Officer||N/A||N/A||1972|
|Mr. Mark Bodenrader||VP of Fin. & Chief Accounting Officer||N/A||N/A||1972|
|Mr. Bryan K. Phillips||Chief Legal Officer||N/A||N/A||1971|
|Mr. Kenneth A. DiPietro||Chief HR Officer||N/A||N/A||1959|
|Ms. Orly Mishan||VP & Chief Bus. Officer||N/A||N/A||1972|
|Ms. Kathleen Tregoning||Chief Corp. Affairs Officer||N/A||N/A||1971|
Cerevel Therapeutics Holdings, Inc. operates as a clinical-stage biopharmaceutical company that engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in an ongoing Phase Ib multiple ascending dose and pharmacokinetic/pharmacodynamic trials for the treatment of patients with schizophrenia; and CVL-865, a PAM that is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as intends to initiate a Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase III program for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I single ascending dose trials for the treatment of substance use disorder. It is also involved in the development of various preclinical portfolio for various neuroscience indications. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Cerevel Therapeutics Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.